Volume 5 Supplement 1
Recommendations for the development of national plans for rare diseases
© Van der Zeijden and Huizer; licensee BioMed Central Ltd. 2010
Published: 19 October 2010
Rare diseases are a threat to the health of EU citizens, in so far as they are life-threatening or chronically debilitating diseases with a low prevalence and a high level of complexity. Despite their rarity, there are so many different types of rare diseases that millions of people are affected. The focus on rare diseases and the recognition of the fact that rare diseases have common issues in a public health perspective and require specifically targeted policies, is a relatively new achievement in most EU member states. There is at present great variability among countries about the type of services provided to rare disease patients and the accessibility to these services. Following the Council Recommendations, each Member State should (preferably by the end of 2013) establish and implement plans or strategies for rare diseases at the appropriate level. The aim is to ensure that all patients with a rare disease in Europe have equal access to high-quality care, including diagnostics, treatments and rehabilitation. The European Project for Rare Diseases National Plans Development (EUROPLAN), has the task of elaborating documents to facilitate the establishment and implementation of National Plans or Strategies. EUROPLAN has defined a National Plan or Strategy as a set of integrated and comprehensive health and social policy actions for rare diseases, to be developed and implemented at national level, and characterised by identified objectives to be achieved within a specified timeframe. The EUROPLAN guidance document (recommendations) provides a set of “tools and examples” on how activities for rare diseases can be organised at national (and European) level on different areas, e.g. the coding (and traceability) of rare diseases, research, centres of expertise and the empowerment of patient organisations for rare diseases.
This article is published under license to BioMed Central Ltd.